A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction

Saktimayee M. Roy, George Minasov, Ottavio Arancio, Laura W. Chico, Linda J. Van Eldik, Wayne F Anderson, Jeffrey C. Pelletier, D Martin Watterson*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

The p38αMAPK is a serine/threonine protein kinase and a key node in the intracellular signaling networks that transduce and amplify stress signals into physiological changes. A preponderance of preclinical data and clinical observations established p38αMAPK as a brain drug discovery target involved in neuroinflammatory responses and synaptic dysfunction in multiple degenerative and neuropsychiatric brain disorders. We summarize the discovery of highly selective, brain-penetrant, small molecule p38αMAPK inhibitors that are efficacious in diverse animal models of neurologic disorders. A crystallography and pharmacoinformatic approach to fragment expansion enabled the discovery of an efficacious hit. The addition of secondary pharmacology screens to refinement delivered lead compounds with improved selectivity, appropriate pharmacodynamics, and efficacy. Safety considerations and additional secondary pharmacology screens drove optimization that delivered the drug candidate MW01-18-150SRM (MW150), currently in early stage clinical trials.

Original languageEnglish (US)
Pages (from-to)5298-5311
Number of pages14
JournalJournal of Medicinal Chemistry
Volume62
Issue number11
DOIs
StatePublished - Jun 13 2019

Fingerprint

Nervous System Diseases
Pharmacology
Crystallography
Protein-Serine-Threonine Kinases
Brain
Brain Diseases
Drug Discovery
Animal Models
Clinical Trials
Safety
Pharmaceutical Preparations
Cognitive Dysfunction

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

@article{885dfe6e07784614a5adcf013cb462c7,
title = "A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction",
abstract = "The p38αMAPK is a serine/threonine protein kinase and a key node in the intracellular signaling networks that transduce and amplify stress signals into physiological changes. A preponderance of preclinical data and clinical observations established p38αMAPK as a brain drug discovery target involved in neuroinflammatory responses and synaptic dysfunction in multiple degenerative and neuropsychiatric brain disorders. We summarize the discovery of highly selective, brain-penetrant, small molecule p38αMAPK inhibitors that are efficacious in diverse animal models of neurologic disorders. A crystallography and pharmacoinformatic approach to fragment expansion enabled the discovery of an efficacious hit. The addition of secondary pharmacology screens to refinement delivered lead compounds with improved selectivity, appropriate pharmacodynamics, and efficacy. Safety considerations and additional secondary pharmacology screens drove optimization that delivered the drug candidate MW01-18-150SRM (MW150), currently in early stage clinical trials.",
author = "Roy, {Saktimayee M.} and George Minasov and Ottavio Arancio and Chico, {Laura W.} and {Van Eldik}, {Linda J.} and Anderson, {Wayne F} and Pelletier, {Jeffrey C.} and Watterson, {D Martin}",
year = "2019",
month = "6",
day = "13",
doi = "10.1021/acs.jmedchem.9b00058",
language = "English (US)",
volume = "62",
pages = "5298--5311",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "11",

}

A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction. / Roy, Saktimayee M.; Minasov, George; Arancio, Ottavio; Chico, Laura W.; Van Eldik, Linda J.; Anderson, Wayne F; Pelletier, Jeffrey C.; Watterson, D Martin.

In: Journal of Medicinal Chemistry, Vol. 62, No. 11, 13.06.2019, p. 5298-5311.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction

AU - Roy, Saktimayee M.

AU - Minasov, George

AU - Arancio, Ottavio

AU - Chico, Laura W.

AU - Van Eldik, Linda J.

AU - Anderson, Wayne F

AU - Pelletier, Jeffrey C.

AU - Watterson, D Martin

PY - 2019/6/13

Y1 - 2019/6/13

N2 - The p38αMAPK is a serine/threonine protein kinase and a key node in the intracellular signaling networks that transduce and amplify stress signals into physiological changes. A preponderance of preclinical data and clinical observations established p38αMAPK as a brain drug discovery target involved in neuroinflammatory responses and synaptic dysfunction in multiple degenerative and neuropsychiatric brain disorders. We summarize the discovery of highly selective, brain-penetrant, small molecule p38αMAPK inhibitors that are efficacious in diverse animal models of neurologic disorders. A crystallography and pharmacoinformatic approach to fragment expansion enabled the discovery of an efficacious hit. The addition of secondary pharmacology screens to refinement delivered lead compounds with improved selectivity, appropriate pharmacodynamics, and efficacy. Safety considerations and additional secondary pharmacology screens drove optimization that delivered the drug candidate MW01-18-150SRM (MW150), currently in early stage clinical trials.

AB - The p38αMAPK is a serine/threonine protein kinase and a key node in the intracellular signaling networks that transduce and amplify stress signals into physiological changes. A preponderance of preclinical data and clinical observations established p38αMAPK as a brain drug discovery target involved in neuroinflammatory responses and synaptic dysfunction in multiple degenerative and neuropsychiatric brain disorders. We summarize the discovery of highly selective, brain-penetrant, small molecule p38αMAPK inhibitors that are efficacious in diverse animal models of neurologic disorders. A crystallography and pharmacoinformatic approach to fragment expansion enabled the discovery of an efficacious hit. The addition of secondary pharmacology screens to refinement delivered lead compounds with improved selectivity, appropriate pharmacodynamics, and efficacy. Safety considerations and additional secondary pharmacology screens drove optimization that delivered the drug candidate MW01-18-150SRM (MW150), currently in early stage clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=85065507048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065507048&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.9b00058

DO - 10.1021/acs.jmedchem.9b00058

M3 - Article

C2 - 30978288

AN - SCOPUS:85065507048

VL - 62

SP - 5298

EP - 5311

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 11

ER -